Jia Jie Biomedical Co Ltd (4109) — Cash Flow-to-Debt Ratio
Jia Jie Biomedical Co Ltd (4109) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of NT$11.32 Million could theoretically repay 0% of its total liabilities (NT$174.89 Million) in one year. See Jia Jie Biomedical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jia Jie Biomedical Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Jia Jie Biomedical Co Ltd across 11 annual periods. Also explore Jia Jie Biomedical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jia Jie Biomedical Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Jia Jie Biomedical Co Ltd. For market capitalisation and broader financial context, see 4109 market cap.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | NT$21.34 Million | NT$174.89 Million | ▼ -66.1% |
| 2024 | 0.36x | NT$44.35 Million | NT$123.08 Million | ▲ +2851.1% |
| 2023 | -0.01x | NT$-4.49 Million | NT$342.69 Million | ▲ +88.1% |
| 2022 | -0.11x | NT$-8.78 Million | NT$80.00 Million | ▼ -317.0% |
| 2021 | 0.05x | NT$4.37 Million | NT$86.47 Million | ▼ -84.8% |
| 2020 | 0.33x | NT$27.10 Million | NT$81.44 Million | ▲ +116.7% |
| 2019 | 0.15x | NT$24.71 Million | NT$160.92 Million | ▲ +574.2% |
| 2018 | -0.03x | NT$-13.10 Million | NT$404.40 Million | ▼ -46.6% |
| 2017 | -0.02x | NT$-13.73 Million | NT$621.58 Million | ▲ +80.2% |
| 2016 | -0.11x | NT$-76.54 Million | NT$684.91 Million | ▼ -181.0% |
| 2015 | 0.14x | NT$82.22 Million | NT$595.84 Million | — |